Chicago Capital Management LLC Invests $21.42 Million in Albany Molecular Research, Inc. (NASDAQ:AMRI)

Chicago Capital Management LLC acquired a new stake in shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 986,958 shares of the biotechnology company’s stock, valued at approximately $21,417,000. Albany Molecular Research comprises 4.8% of Chicago Capital Management LLC’s portfolio, making the stock its 9th largest position. Chicago Capital Management LLC owned 2.37% of Albany Molecular Research as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Comerica Bank increased its position in shares of Albany Molecular Research by 5.7% in the fourth quarter. Comerica Bank now owns 24,940 shares of the biotechnology company’s stock valued at $452,000 after buying an additional 1,349 shares during the period. State Street Corp increased its position in Albany Molecular Research by 7.2% in the fourth quarter. State Street Corp now owns 512,819 shares of the biotechnology company’s stock valued at $9,623,000 after buying an additional 34,448 shares during the last quarter. Renaissance Technologies LLC increased its position in Albany Molecular Research by 3.1% in the fourth quarter. Renaissance Technologies LLC now owns 357,900 shares of the biotechnology company’s stock valued at $6,714,000 after buying an additional 10,658 shares during the last quarter. Thrivent Financial for Lutherans increased its position in Albany Molecular Research by 4.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 11,990 shares of the biotechnology company’s stock valued at $225,000 after buying an additional 550 shares during the last quarter. Finally, Teachers Advisors LLC increased its position in Albany Molecular Research by 0.5% in the fourth quarter. Teachers Advisors LLC now owns 41,916 shares of the biotechnology company’s stock valued at $786,000 after buying an additional 198 shares during the last quarter. 73.43% of the stock is owned by institutional investors and hedge funds.

Shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) traded up 0.05% during midday trading on Friday, hitting $21.76. 629,856 shares of the stock traded hands. The stock’s market capitalization is $929.04 million. Albany Molecular Research, Inc. has a 52 week low of $13.01 and a 52 week high of $22.17. The firm has a 50-day moving average price of $21.70 and a 200-day moving average price of $18.08.

Albany Molecular Research (NASDAQ:AMRI) last released its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.01. Albany Molecular Research had a positive return on equity of 11.97% and a negative net margin of 11.26%. The business had revenue of $163.80 million for the quarter, compared to the consensus estimate of $161.43 million. During the same quarter in the previous year, the company posted $0.07 EPS. The company’s revenue was up 55.1% compared to the same quarter last year. On average, equities analysts predict that Albany Molecular Research, Inc. will post $1.13 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.com-unik.info/2017/08/12/986958-shares-in-albany-molecular-research-inc-nasdaqamri-acquired-by-chicago-capital-management-llc-updated-updated-updated.html.

A number of research firms have commented on AMRI. First Analysis lowered shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a research report on Monday, June 12th. J P Morgan Chase & Co lowered shares of Albany Molecular Research from an “overweight” rating to a “neutral” rating in a research report on Thursday, June 8th. BidaskClub upgraded shares of Albany Molecular Research from a “sell” rating to a “hold” rating in a research report on Friday. William Blair lowered shares of Albany Molecular Research from an “outperform” rating to a “market perform” rating in a research report on Tuesday, June 6th. Finally, Morgan Stanley downgraded shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 price target for the company. in a research note on Thursday, May 11th. They noted that the move was a valuation call. Five investment analysts have rated the stock with a hold rating, Albany Molecular Research currently has a consensus rating of “Hold” and a consensus target price of $18.00.

About Albany Molecular Research

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)

What are top analysts saying about Albany Molecular Research Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Albany Molecular Research Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit